• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基线血小板减少对择期经皮冠状动脉介入治疗患者院内结局的影响。

Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention.

作者信息

Shiraishi Jun, Koshi Nariko, Matsubara Yuki, Nishimura Tetsuro, Ito Daisuke, Kimura Masayoshi, Kishita Eigo, Nakagawa Yusuke, Hyogo Masayuki, Sawada Takahisa

机构信息

Department of Cardiology, Kyoto First Red Cross Hospital, Japan.

出版信息

Intern Med. 2019 Jun 15;58(12):1681-1688. doi: 10.2169/internalmedicine.2063-18. Epub 2019 Feb 25.

DOI:10.2169/internalmedicine.2063-18
PMID:30799350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6630129/
Abstract

Objective The purpose of the present study was to examine the relationship between thrombocytopenia at baseline and in-hospital outcomes in unselected patients undergoing elective percutaneous coronary intervention (PCI) in Japan. Methods Among a total of 1,247 consecutive elective PCI-treated patients, patients with a baseline platelet count 150,000-449,000/μL and 50,000-149,000/μL were assigned to the normal platelet (n=1,009) and thrombocytopenia (n=226) groups, respectively. The thrombocytopenia group was further divided into the mild thrombocytopenia (100,000-149,000/μL, n=187) and moderate thrombocytopenia (50,000-99,000/μL, n=39) groups. Results The angiographic success rate of PCI and in-hospital mortality rate did not differ to a statistically significant extent between the normal platelet and thrombocytopenia groups or between the mild thrombocytopenia and moderate thrombocytopenia groups, whereas the moderate thrombocytopenia group had a significantly higher rate of access site-related bleeding complications than the normal platelet group. According to a multivariate analysis, moderate thrombocytopenia was an independent predictor of access site-related bleeding complications. Conclusion Among patients with mild to moderate thrombocytopenia, elective PCI might be feasible and effective in the short term; however, more attention should be paid to access site-related bleeding complications, particularly in patients with moderate thrombocytopenia.

摘要

目的 本研究旨在探讨在日本接受择期经皮冠状动脉介入治疗(PCI)的未选择患者中,基线血小板减少与住院结局之间的关系。方法 在总共1247例连续接受择期PCI治疗的患者中,基线血小板计数为150,000 - 449,000/μL和50,000 - 149,000/μL的患者分别被分配到正常血小板组(n = 1,009)和血小板减少组(n = 226)。血小板减少组进一步分为轻度血小板减少组(100,000 - 149,000/μL,n = 187)和中度血小板减少组(50,000 - 99,000/μL,n = 39)。结果 PCI的血管造影成功率和住院死亡率在正常血小板组与血小板减少组之间或轻度血小板减少组与中度血小板减少组之间没有统计学上的显著差异,而中度血小板减少组与穿刺部位相关的出血并发症发生率显著高于正常血小板组。根据多变量分析,中度血小板减少是穿刺部位相关出血并发症的独立预测因素。结论 在轻度至中度血小板减少的患者中,择期PCI短期内可能是可行且有效的;然而,应更加关注穿刺部位相关的出血并发症,特别是在中度血小板减少的患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/db0ce8468c6f/1349-7235-58-1681-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/74cdee3d50f5/1349-7235-58-1681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/e024228a4e1e/1349-7235-58-1681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/db0ce8468c6f/1349-7235-58-1681-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/74cdee3d50f5/1349-7235-58-1681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/e024228a4e1e/1349-7235-58-1681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cae/6630129/db0ce8468c6f/1349-7235-58-1681-g003.jpg

相似文献

1
Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention.基线血小板减少对择期经皮冠状动脉介入治疗患者院内结局的影响。
Intern Med. 2019 Jun 15;58(12):1681-1688. doi: 10.2169/internalmedicine.2063-18. Epub 2019 Feb 25.
2
Impact of baseline thrombocytopenia on the long-term outcome of patients undergoing elective percutaneous coronary intervention: An analysis of 9,897 consecutive patients.基线血小板减少对择期经皮冠状动脉介入治疗患者长期预后的影响:连续 9897 例患者的分析。
Catheter Cardiovasc Interv. 2019 Feb 15;93(S1):764-771. doi: 10.1002/ccd.28030. Epub 2018 Dec 26.
3
Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention.基线血小板减少是接受经皮冠状动脉介入治疗患者住院死亡率的一个预测指标。
Am Heart J. 2008 Jul;156(1):120-4. doi: 10.1016/j.ahj.2008.02.003. Epub 2008 Apr 3.
4
Impact of Baseline Thrombocytopenia on Bleeding and Mortality After Percutaneous Coronary Intervention.基线血小板减少症对经皮冠状动脉介入治疗后出血和死亡率的影响。
Am J Cardiol. 2018 Jun 1;121(11):1304-1314. doi: 10.1016/j.amjcard.2018.02.010. Epub 2018 Mar 1.
5
The impact of acquired thrombocytopenia on long-term outcomes of patients undergoing elective percutaneous coronary intervention: An analysis of 8,271 consecutive patients.获得性血小板减少症对择期经皮冠状动脉介入治疗患者长期预后的影响:对8271例连续患者的分析
Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):558-565. doi: 10.1002/ccd.27498. Epub 2018 Jan 25.
6
Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention.口服抗凝药物的心房颤动患者行经皮冠状动脉介入治疗后发生血小板减少症。
Am J Cardiol. 2013 Aug 15;112(4):493-8. doi: 10.1016/j.amjcard.2013.04.007. Epub 2013 May 11.
7
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).经皮冠状动脉介入治疗后获得性血小板减少症的发生率、预测因素和结局:CHAMPION 试验(替卡格雷与标准治疗以实现血小板抑制最佳管理)的汇总、患者水平分析。
Circ Cardiovasc Interv. 2018 Apr;11(4):e005635. doi: 10.1161/CIRCINTERVENTIONS.117.005635.
8
Effect of Preprocedural Thrombocytopenia on Prognosis After Percutaneous Coronary Intervention.术前血小板减少对经皮冠状动脉介入治疗后预后的影响。
Mayo Clin Proc. 2016 Aug;91(8):1035-44. doi: 10.1016/j.mayocp.2016.05.008.
9
Baseline thrombocytopenia in acute coronary syndrome: The lower, the worse.急性冠状动脉综合征中的基线血小板减少症:越低,越差。
Int J Cardiol. 2021 Jun 1;332:1-7. doi: 10.1016/j.ijcard.2021.03.059. Epub 2021 Mar 27.
10
Impact of Access Site Practice on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Thrombolysis for ST-Segment Elevation Myocardial Infarction in the United Kingdom: An Insight From the British Cardiovascular Intervention Society Dataset.英国经溶栓治疗的 ST 段抬高型心肌梗死患者行经皮冠状动脉介入治疗中穿刺部位操作对临床结局的影响:来自英国心血管介入学会数据集的见解。
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2258-2265. doi: 10.1016/j.jcin.2017.07.049.

引用本文的文献

1
Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma.多发性骨髓瘤自体干细胞移植后血小板减少期间阿司匹林的使用与出血事件
Front Oncol. 2023 Apr 27;13:1168120. doi: 10.3389/fonc.2023.1168120. eCollection 2023.
2
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.欧洲血液学协会癌症血小板减少患者抗血栓治疗管理指南
Hemasphere. 2022 Jul 13;6(8):e750. doi: 10.1097/HS9.0000000000000750. eCollection 2022 Aug.
3
Development of a Clinical Risk Score for Prediction of Life-Threatening Arrhythmia Events in Patients with ST Elevated Acute Coronary Syndrome after Primary Percutaneous Coronary Intervention.

本文引用的文献

1
Impact of Baseline Thrombocytopenia on Bleeding and Mortality After Percutaneous Coronary Intervention.基线血小板减少症对经皮冠状动脉介入治疗后出血和死亡率的影响。
Am J Cardiol. 2018 Jun 1;121(11):1304-1314. doi: 10.1016/j.amjcard.2018.02.010. Epub 2018 Mar 1.
2
Stent-less percutaneous coronary intervention using rotational atherectomy and drug-coated balloon: A case series and a mini review.使用旋磨术和药物涂层球囊的无支架经皮冠状动脉介入治疗:病例系列及小型综述
Cardiovasc Revasc Med. 2018 Sep;19(6):705-711. doi: 10.1016/j.carrev.2018.02.007. Epub 2018 Feb 12.
3
Optical frequency domain imaging-guided rotational atherectomy followed by drug-coated balloon dilation to the non-calcified lesion in a patient with severe thrombocytopenia.
ST 段抬高型急性冠状动脉综合征患者经皮冠状动脉介入治疗后发生致命性心律失常事件的临床风险评分的制定。
Int J Environ Res Public Health. 2022 Feb 10;19(4):1997. doi: 10.3390/ijerph19041997.
4
Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention.血小板减少症对行经皮冠状动脉介入治疗患者住院结局的影响。
Cardiovasc Ther. 2021 Jan 13;2021:8836450. doi: 10.1155/2021/8836450. eCollection 2021.
5
Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.基线时存在血小板减少症的患者经皮冠状动脉介入治疗后双联抗血小板治疗:一项荟萃分析。
BMC Pharmacol Toxicol. 2020 Apr 25;21(1):31. doi: 10.1186/s40360-020-00409-2.
光学频域成像引导下的旋磨术,随后对一名严重血小板减少症患者的非钙化病变进行药物涂层球囊扩张术。
Cardiovasc Interv Ther. 2018 Oct;33(4):395-397. doi: 10.1007/s12928-017-0493-6. Epub 2017 Sep 30.
4
Effect of Preprocedural Thrombocytopenia on Prognosis After Percutaneous Coronary Intervention.术前血小板减少对经皮冠状动脉介入治疗后预后的影响。
Mayo Clin Proc. 2016 Aug;91(8):1035-44. doi: 10.1016/j.mayocp.2016.05.008.
5
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.2016年美国心脏病学会/美国心脏协会关于冠状动脉疾病患者双联抗血小板治疗时长的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组报告:2011年美国心脏病学会基金会/美国心脏协会/心血管造影和介入学会经皮冠状动脉介入治疗指南、2011年美国心脏病学会基金会/美国心脏协会冠状动脉旁路移植手术指南、2012年美国心脏病学会/美国心脏协会/美国内科医师学会/美国胸外科医师协会/美国预防心脏病学会/心血管造影和介入学会/美国胸外科医师学会稳定型缺血性心脏病患者诊断和管理指南、2013年美国心脏病学会基金会/美国心脏协会ST段抬高型心肌梗死管理指南、2014年美国心脏协会/美国心脏病学会非ST段抬高型急性冠状动脉综合征患者管理指南以及2014年美国心脏病学会/美国心脏协会非心脏手术患者围手术期心血管评估和管理指南的更新
Circulation. 2016 Sep 6;134(10):e123-55. doi: 10.1161/CIR.0000000000000404. Epub 2016 Mar 29.
6
Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention.基线血小板减少症对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者缺血性结局的影响。
Can J Cardiol. 2016 Feb;32(2):226-33. doi: 10.1016/j.cjca.2015.05.020. Epub 2015 Jun 5.
7
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者中桡动脉与股动脉入路的随机多中心试验。
Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.
8
Antiplatelet therapy for patients with stable ischemic heart disease and baseline thrombocytopenia: ask the hematologist.稳定型缺血性心脏病合并基线血小板减少症患者的抗血小板治疗:咨询血液科医生。
Platelets. 2014;25(6):455-60. doi: 10.3109/09537104.2013.828029. Epub 2013 Sep 27.
9
Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.西罗莫司洗脱支架置入术后非常晚期支架血栓形成和晚期靶病变血运重建:j-Cypher 注册研究的 5 年结果。
Circulation. 2012 Jan 31;125(4):584-91. doi: 10.1161/CIRCULATIONAHA.111.046599. Epub 2011 Dec 27.
10
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.基线血小板减少对直接经皮冠状动脉介入治疗 ST 段抬高型心肌梗死患者早期和晚期结局的影响:来自急性心肌梗死血管重建和支架置入(HORIZONS-AMI)试验的分析。
Am Heart J. 2011 Feb;161(2):391-6. doi: 10.1016/j.ahj.2010.11.001.